Immuneering

About Immuneering

Immuneering Corp is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer. Leveraging a proprietary disease-agnostic platform, Immuneering designs and advances small molecule drug candidates to target a broad range of oncologic diseases. Its lead product candidate, IMM-1-104, is a dual-MEK inhibitor in Phase 1/2a clinical trials for advanced solid tumors, including pancreatic, melanoma, colorectal, and non-small cell lung cancer. The company aims to improve treatment tolerability and expand indications for cancer patients through innovative approaches in biology, chemistry, and translational planning.